- Home
- HURA vs BDTX Comparison
HURA vs BDTX Comparison
Compare HURA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | BDTX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.0M | 104.0M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HURA | BDTX |
|---|---|---|
| Price | $1.72 | $1.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $8.04 | ★ $10.00 |
| AVG Volume (30 Days) | 366.5K | ★ 852.2K |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.93 | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.60 |
| 52 Week High | $3.43 | $4.94 |
Technical Indicators
Market Signals| Indicator | HURA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 47.62 |
| Support Level | $1.27 | $1.65 |
| Resistance Level | $2.22 | $1.93 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.86 | 33.33 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.